Lauren Riker - Jan 18, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Senior Vice President, Finance
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Jan 18, 2022
Transactions value $
-$135,405
Form type
4
Date filed
1/20/2022, 06:22 PM
Previous filing
Jan 10, 2022
Next filing
Mar 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $27K +2.5K +16.5% $10.81 17.7K Jan 18, 2022 Direct F1
transaction PCRX Common Stock Sale -$162K -2.5K -14.16% $64.97 15.2K Jan 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2.5K -21.19% $0.00 9.3K Jan 18, 2022 Common Stock 2.5K $10.81 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.